Columbia Labs' Advantage 24 will be studied in United Nations' HIV/STD prevention trial.
This article was originally published in The Tan Sheet
Executive Summary
U.N. STUDY OF ADVANTAGE 24 FOR PREVENTION OF HIV and other sexually transmitted diseases will assess the effectiveness of the nonoxynol-9-containing spermicide for prevention of heterosexual transmission of the diseases, Columbia Labs announced May 14. The company is donating Advantage 24 for use in the project; the study will be funded and conducted by the United Nations Global Program on HIV/AIDS (UNAIDS).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning